ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Company Details
- Employees
- 102
- Founded
- -
- Address
- Menlo Park, California & Durham, North Carolina, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://recodetx.com/
- Keywords
- RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, Biotechnology.
- HQ
- Menlo Park, California & Durham, North Carolina
Recode Therapeutics Questions
Recode Therapeutics's website is https://recodetx.com/
Recode Therapeutics's LinkedIn profile is https://www.linkedin.com/company/recode-therapeutics
Recode Therapeutics has
102 employees.
View email and phone details for 102
employees at Recode Therapeutics.
Recode Therapeutics's industry is
Biotechnology Research
Recode Therapeutics's top competitors are
Bridgebio,
Allogene Therapeutics,
Denali Therapeutics,
Verve Therapeutics,
Genentech,
Intellia Therapeutics, Inc.,
Vertex Pharmaceuticals,
Beam Therapeutics,
Askbio Inc.,
Xaira Therapeutics.
Recode Therapeutics's categories are Biotechnology Research
Recode Therapeutics's founding year is 2015
